Professional Documents
Culture Documents
IDU in Eurasia
MSM trends
1.5 million
200,000 in ‘05
IDU
7.6 million
830,000 in
‘05
Heterosexual
MSM
IDU
12.1 million
1.3 million in ‘05
Heterosexual
Source: UNAIDS 2006 Report on the Global AIDS Pandemic
Ecological Model for HIV Risk
Blood
Semen
18,000 Vaginal
11,000
Fluid Amniotic
7,000 Fluid
4,000 Saliva
1
Flu-like Symptoms
Or Symptom-free AIDS Symptoms
No Symptoms
----
Infection Virus
Occurs
Antibody
----
• The immune
system weakens
• The illnesses
become more
severe leading to
an AIDS diagnosis
Opportunistic Infections associated
with AIDS
• Bacterial
– Tuberculosis (TB)
– Strep pneumonia
• Viral
– Kaposi Sarcoma
– Herpes
– Influenza (flu)
Opportunistic Infections associated
with AIDS
• Parasitic
– Pneumocystis carinii
• Fungal
– Candida
– Cryptococcus
Modes of HIV/AIDS Transmission
Through Bodily Fluids
• Blood products
• Semen
• Vaginal fluids
• Breast Milk
Through IV Drug Use
• Sharing Needles
– Without sterilization
• Increases the chances of contracting HIV
Through Sex
• Intercourse (penile penetration into the
vagina)
• Oral
• Anal
• Digital Sex
Mother-to-Baby
• Before Birth
• During Birth
• Postpartum
– After the birth
Testing Options for HIV
Importance of Early Testing
and Diagnosis
• Allows for early treatment to maintain and
stabilize the immune system response
IFA (Reactive)
• Blood
• Urine
• Oral
Blood Detection Tests
• Enzyme-Linked Immunosorbent Assay/Enzyme
Immunoassay (ELISA/EIA)
• Radio Immunoprecipitation Assay/Indirect
Fluorescent Antibody Assay (RIP/IFA)
• Polymerase Chain Reaction (PCR)
• Western Blot Confirmatory test
Urine Testing
Repeat every
6 months for continued
Indeterminate Negative Positive
High risk behavior
Repeat at Repeat at
End Testing Negative 3 weeks 2-4 months
HIV
+
Counseling
Pre-test Counseling
• Transmission
• Prevention
• Risk Factors
• Voluntary & Confidential
• Reportability of Positive Test Results
Post-test Counseling
• Clarifies test results
• Need for additional testing
• Promotion of safe behavior
• Release of results
Treatment Options
Antiretroviral Drugs
• Nucleoside Reverse Transcriptase
inhibitors
– AZT (Zidovudine)
• Non-Nucleoside Transcriptase inhibitors
– Viramune (Nevirapine)
• Protease inhibitors
– Norvir (Ritonavir)
Opportunistic Infection Treatment
• Non-profit
Organization, which
provides sterile
needles in
exchange for
contaminated ones
HIV Post Exposure
Prophylaxis
HIV Occupational Exposure
• Review facility policy and report the incident
• Medical follow-up is necessary to determine
the exposure risk and course of treatment
• Baseline and follow-up HIV testing
• Four week course of medication initiated
one to two hours after exposure
• AZT (200mg)-TID +lamivudine(3TC)
(150mg)BID x 4days
• Nelfinavir (750 mg) TID ,AZT/3TC
• Exposure precautions practiced
HIV Non-Occupational
Exposure
PREVENTION --- FIRST
• No data exists on the efficacy of antiretroviral
medication after non-occupational exposures
• The health care provider and patient may
decide to use antiretroviral therapy after
weighing the risks and benefits
• Antiretrovirals should not be used for those
with low-risk transmissions or exposures
occurring more than 72 hours after exposure
Why the world needs an AIDS vaccine